×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OPK – opko health, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OPK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/16
01:58 pm
opk
“CNBC CURES: DEFYING RARE DISEASE” WITH BECKY QUICK TO PREMIERE ON THURSDAY, MARCH 19 AT 7PM ET [CNBC]
Low
Report
“CNBC CURES: DEFYING RARE DISEASE” WITH BECKY QUICK TO PREMIERE ON THURSDAY, MARCH 19 AT 7PM ET [CNBC]
3/11
05:27 pm
opk
GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/11
05:26 pm
opk
Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing [Yahoo! Finance]
Low
Report
Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing [Yahoo! Finance]
3/10
08:46 am
opk
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C [Yahoo! Finance]
Low
Report
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C [Yahoo! Finance]
3/9
08:42 am
opk
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership [Yahoo! Finance]
Low
Report
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership [Yahoo! Finance]
3/2
10:56 am
opk
OPKO Health (OPK) had its price target lowered by Barrington Research from $2.25 to $1.50. They now have an "outperform" rating on the stock.
Medium
Report
OPKO Health (OPK) had its price target lowered by Barrington Research from $2.25 to $1.50. They now have an "outperform" rating on the stock.
2/27
08:00 am
opk
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
Low
Report
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
2/27
01:35 am
opk
OPKO Health Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
OPKO Health Q4 Earnings Call Highlights [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/5
OPKO Health's BioReference Laboratories to Introduce Coronavirus Disease (COVID-19) Test
29.2%
4/20 Form 4 Opko Health, Inc. For: Apr 17 Filed by: FROST PHILLIP MD ET AL 16.5%
3/17 OPKO Health's BioReference Laboratories and NYC Health + Hospitals Enter into Laboratory Collaboration to Provide Testing for Coronavirus Disease 2019 (COVID-19) 13.1%
3/4 Form 4 Opko Health, Inc. For: Mar 03 Filed by: Frost Gamma Investments Trust 12.2%
3/13 Form 4 Opko Health, Inc. For: Mar 12 Filed by: Japour Anthony J 11.8%
4/6 Form 4 Opko Health, Inc. For: Apr 03 Filed by: FROST PHILLIP MD ET AL 11.6%
6/28 Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test 9.9%
4/8 Form 4 Opko Health, Inc. For: Apr 07 Filed by: Frost Gamma Investments Trust 7.8%
9/23 Form 8-K Opko Health, Inc. For: Sep 21 6.5%
3/10 Opko Health Inc. (NASDAQ: OPK) had its price target raised by analysts at Piper Sandler from to . 6.2%
4/20 Form 4 Opko Health, Inc. For: Apr 17 Filed by: FROST PHILLIP MD ET AL 16.5%
3/17 OPKO Health's BioReference Laboratories and NYC Health + Hospitals Enter into Laboratory Collaboration to Provide Testing for Coronavirus Disease 2019 (COVID-19) 13.1%
3/4 Form 4 Opko Health, Inc. For: Mar 03 Filed by: Frost Gamma Investments Trust 12.2%
3/13 Form 4 Opko Health, Inc. For: Mar 12 Filed by: Japour Anthony J 11.8%
4/6 Form 4 Opko Health, Inc. For: Apr 03 Filed by: FROST PHILLIP MD ET AL 11.6%
6/28 Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test 9.9%
4/8 Form 4 Opko Health, Inc. For: Apr 07 Filed by: Frost Gamma Investments Trust 7.8%
9/23 Form 8-K Opko Health, Inc. For: Sep 21 6.5%
3/10 Opko Health Inc. (NASDAQ: OPK) had its price target raised by analysts at Piper Sandler from to . 6.2%
TOP News Decliners
3/9
Edited Transcript of OPK earnings conference call or presentation 26-Feb-20 9:30pm GMT [Yahoo! Finance News]
-26.0%
5/7 Q1/2019 3/31/2019 EPS -0.140 ZacksConsensus -0.060 ActVsEst (0.080) - Miss -14.3%
10/24 OPKO Health, Inc. Announces Pricing of its Offering of Common Stock -14.3%
10/24 Form 424B5 Opko Health, Inc. -14.2%
3/13 Coronavirus activity roundup - healthcare [Seeking Alpha] -11.6%
3/7 Opko Health Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at Piper Sandler. -10.5%
3/20 Form 4 Opko Health, Inc. For: Mar 19 Filed by: Frost Gamma Investments Trust -8.5%
10/21 OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency -7.8%
11/5 OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results -7.5%
5/13 Form 4 Opko Health, Inc. For: May 10 Filed by: FROST PHILLIP MD ET AL -6.7%
5/7 Q1/2019 3/31/2019 EPS -0.140 ZacksConsensus -0.060 ActVsEst (0.080) - Miss -14.3%
10/24 OPKO Health, Inc. Announces Pricing of its Offering of Common Stock -14.3%
10/24 Form 424B5 Opko Health, Inc. -14.2%
3/13 Coronavirus activity roundup - healthcare [Seeking Alpha] -11.6%
3/7 Opko Health Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at Piper Sandler. -10.5%
3/20 Form 4 Opko Health, Inc. For: Mar 19 Filed by: Frost Gamma Investments Trust -8.5%
10/21 OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency -7.8%
11/5 OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results -7.5%
5/13 Form 4 Opko Health, Inc. For: May 10 Filed by: FROST PHILLIP MD ET AL -6.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: